• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals’ Oral GZR18 Tablet Completes First Dosing in Phase I Clinical Trial
    Gan & Lee Pharmaceuticals’ Oral GZR18 Tablet Completes First Dosing in Phase I Clinical Trial
    Date:2024-04-08

    Beijing, China, March 08, 2024 — Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", stock code: 603087.SH) announces today that the first subject has been dosed successfully in a Phase I clinical trial in China for its independently developed innovative oral peptide-class GLP-1 receptor agonist (GLP-1 RA) — GZR18 tablet, aimed at treating Type 2 Diabetes Mellitus (T2DM).


    The single-center, randomized, open-label Phase I clinical study conducted by Gan & Lee Pharmaceuticals aims to evaluate the relative bioavailability, pharmacokinetics, pharmacodynamics, safety, tolerability, and the impact of meal timing on the pharmacokinetics, pharmacodynamics, safety, and tolerability of the GZR18 tablet in healthy adult subjects in China. The trial plans to enroll 116 healthy adult participants.


    Diabetes, a metabolic disease characterized by abnormal glucose metabolism, is primarily due to impaired insulin production or response, leading to ineffective blood glucose maintenance. T2DM, the most common form, constitutes the vast majority of diabetes cases worldwide, with its onset linked to complex causes including genetic factors and poor lifestyle habits, such as lack of exercise and obesity.1 Glucagon-like peptide-1 (GLP-1) is a crucial hormone secreted by intestinal L cells, regulating insulin and glucagon secretion based on blood glucose levels to maintain glucose stability. GLP-1 RAs, developed in recent years, mimic the function of GLP-1 to activate GLP-1 receptors, controlling blood glucose levels. Beyond glucose regulation, GLP-1 RAs have shown clinical benefits, such as aiding weight control and improving non-alcoholic fatty liver disease, gradually becoming the preferred medication for diabetes treatment over traditional insulin therapies. Despite most GLP-1 RAs being injectable, oral GLP-1 RAs, favored for convenience and better patient experience, represent a new research direction in diabetes treatment.2


    In the development of oral GLP-1 RAs, challenges for peptide-class drugs include overcoming gastrointestinal structural and functional barriers, like proteolytic degradation and the gastrointestinal wall barrier. Scientists enhance absorption and bioavailability in the gastrointestinal tract by integrating absorption enhancers into peptide medications. GZR18 tablet employs an advanced oral delivery technique, enhancing drug absorption in the stomach and extending the drug's half-life by resisting gastric protease degradation, thereby improving the bioavailability of GZR18. Prior clinical studies of GZR18 injection for T2DM and obesity/overweight management in China and the USA have preliminarily validated its excellent safety and efficacy. This Phase I clinical trial of the GZR18 tablet in China marks the first-in-human clinical study of GZR18's oral formulation, aiming to expedite the development of GZR18 and potentially offer patients more convenient treatment options domestically.


    About GZR18

    GZR18, developed by Gan & Lee, is a GLP-1 receptor agonist intended for the treatment of T2DM in adults and for weight management in obese/overweight individuals. Preclinical data suggests that GZR18 has potential benefits in reducing blood glucose levels and weight. Some clinical studies have confirmed its efficacy in these areas, and it has a good safety profile. Currently, the global development of GZR18 has entered the Phase II clinical research stage.


    References:

    1.     Chin J Diabetes Mellitus, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

    2.     Zheng Li, et al., Research Progress of Oral Glucagon-Like Peptide-1 Receptor Agonists and Consideration of Non-clinical Evaluation. Chinese Pharmaceutical Affaris, 2023,(7):825-833. DOI:10.16153/j.1002-7777.2023.07.012


    About Gan & Lee


    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).


    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.




    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號(hào)-1 | 京公網(wǎng)安備 11011202003900號(hào)
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 国产va欧美va在线观看| 欧美一级欧美一级高清| 国内精品久久久久久久久齐齐| 又污又爽又黄的网站| tube8最近日本护士| 精品无码一区二区三区在线| 日本爱恋电影在线观看视频 | 亚洲熟妇av一区二区三区宅男 | 精品爆乳一区二区三区无码AV | 国产在线精品一区二区中文| 亚洲va成无码人在线观看| 北岛玲日韩精品一区二区三区 | 中文字幕第12页| 老子影院午夜伦手机不四虎 | 波多野结衣护士| 国产高清自产拍av在线| 国产精品久久久久久久网站| 亚洲国产精品一区二区成人片国内| 2022久久国产精品免费热麻豆| 欧美性大战久久久久久| 国产精品99久久久精品无码| 九九热在线视频播放| 高潮毛片无遮挡高清免费 | 国产60部真实乱| 99久久精品全部| 波多野结衣绝顶大高潮| 国产成人精品视频一区| 久久人午夜亚洲精品无码区| 色老二精品视频在线观看| 成人人观看的免费毛片| 免费国产黄网站在线观看视频| 2019天天干夜夜操| 最新亚洲春色av无码专区| 国产啊v在线观看| bl文库双性灌尿| 日韩影院在线观看| 啊灬啊灬别停啊灬用力啊免费| √天堂中文www官网| 正在播放西川ゆい在线| 国产特级淫片免费看| 久久久久亚洲AV成人无码电影|